BPC-157 side effects: what the studies report
This reference collects the adverse effects of BPC-157 that published studies describe. The evidence presented is predominantly preclinical [1][7]. The individual modern human reports are small and uncontrolled [9][10][11]; an older controlled-study report is considered in the FDA assessment with reporting limitations [13]. It summarizes research findings and is not medical advice.
Summary
- An orthopaedic systematic review searching through 3 June 2024 included 36 studies: 35 preclinical and one clinical; its authors found no clinical safety data in that eligible set [1]. This is not a conclusion that human observations are absent: later small reports describe them without establishing clinical safety [10][11].
- In the specific single-dose and repeated-dose toxicity tests reported by Xu and colleagues (2020) in mice, rats, rabbits and dogs, the authors reported good tolerance and no serious toxicity. The one notable laboratory change was a lower serum creatinine in dogs at the highest dose [2].
- In the laboratory BPC-157 raised VEGFR2 expression and promoted blood-vessel growth [5]. A literature review names this as the first predicted consequence and labels the resulting risks unverified [4].
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| No serious toxicity reported in the specific Xu (2020) tests | Mice, rats, rabbits, dogs | Single dose: no test-related effects; repeated doses (dogs): well tolerated, no serious toxicity observed in those tests | [2] |
| Lower serum creatinine | Dogs, repeated doses | Seen at 2 mg/kg but not at lower doses; the animals recovered spontaneously after two weeks of withdrawal | [2] |
| Local irritation at the injection site | Animal local tolerance test | Described as mild | [2] |
| Genotoxicity, embryo-fetal toxicity | Animal tests | Not found | [2] |
| Pain or necrosis on injection | A patent claim about BPC-peptide preparations, cited by a review | No clinical frequency given; not an established effect of the vehicles themselves or of every marketed preparation | [4][12] |
| Adverse reactions in soft-tissue healing studies | Mostly small rodent models | Few studies reported any | [6] |
| Safety in inflammatory bowel disease trials | Human trials, author statement | Described as safe by the authors; no adverse-event figures in the abstract | [8] |
What the effects depended on
The one dose-linked finding came from dogs given repeated doses: serum creatinine fell at 2 mg/kg but not at lower doses, and the animals recovered after two weeks without the compound [2]. Route and vehicle also appear in the reports. A 2025 review cites a patent claim about pain or necrosis following BPC-peptide preparations in aqueous solution or saline [4][12]. This is not an established clinical frequency or proof that the vehicle itself caused the effect. A separate pharmacokinetic study measured intramuscular bioavailability of about 14-19% in rats and 45-51% in dogs, with an elimination half-life under 30 minutes [3]. Product quality is a separate variable: the systematic review lists unregulated manufacturing and contamination among possible causes of adverse effects [1]. Dose schedules from the literature are described in the BPC-157 dosing reference.
Serious and rare events
No serious toxicity was observed in the specific Xu and colleagues toxicology tests. A single-dose study showed no test-related effects, and repeated-dose studies in dogs showed no abnormal changes beyond the creatinine finding [2]. The 2025 review adds that no toxic dose has been determined to date [4].
The abstract of a pilot report in 12 women with interstitial cystitis reported no adverse events after local injections around bladder inflammation [10]. Another pilot involved two adults previously exposed to intravenous BPC-157; visits on days 1-3 included laboratory and vital-sign checks and side-effect questions. No side effects were reported [11]. These small uncontrolled observations cannot estimate clinical incidence or long-term risk or establish safety for another route or a particular marketed preparation.
In its 2026 assessment of an older Phase II rectal-preparation meeting abstract, FDA reports 53 randomized participants and 46 completing. Adverse-event withdrawals were three on active treatment and two on placebo, mainly ulcerative-colitis progression according to the authors; arm denominators were not supplied. FDA judged safety reporting inadequate [13]. This is a regulatory account of an abstract, not an independently read full clinical report.
The 2025 review also lists predicted risks that follow from the peptide's mechanism; the first it lists is that promoting blood-vessel growth could matter where a tumour is present. Its authors describe these reactions as unverified and untested [4]. No frequency can be given for any of them.
Limits of the evidence
Most studies are small rodent experiments from a handful of research groups [6]. The 2026 review notes limited human pharmacokinetic data [7]. The 2026 FDA document states that BPC-157 free base and acetate are not components of an FDA-approved drug in the United States [13]. The authors of a 2006 review describe the peptide as safe in inflammatory bowel disease trials, but the abstract gives no adverse-event figures [8]. A shortage of reports is not a shortage of effects: the cited clinical reports and regulatory assessment do not establish safety for a particular marketed preparation [9][10][11][13]. A summary of published findings cannot assess any one person's situation; that belongs with a physician.
FAQ
Does BPC-157 cause side effects?
In the specific Xu and colleagues tests, the authors reported good tolerance and no serious toxicity in the tested animals. They also recorded mild local irritation and a reversible drop in serum creatinine in dogs at the highest dose [2]. The small bladder and intravenous human reports reported no adverse events or side effects, which does not demonstrate safety [10][11]. The separate FDA assessment of an older controlled report identifies inadequate safety reporting [13].
Has BPC-157 been tested for safety in humans?
Within the orthopaedic review searching through 3 June 2024, one of 36 eligible studies concerned knee pain [1]. Its primary retrospective abstract distinguishes 17 charts and 16 respondents: 12 received BPC-157 alone and four BPC-157 with TB4. This is not 16 monotherapy participants or evidence of systematic adverse-event monitoring [9]. Separate small bladder and intravenous observations are described above [10][11]. FDA assesses the older controlled Phase II study through a meeting abstract with inadequate reporting [13]. A 2006 review calls the peptide safe in inflammatory bowel disease trials without adverse-event figures in its abstract [8]. These different samples do not form a total of unique participants.
Could BPC-157 raise cancer risk?
The sources behind this page do not report that. The concern is theoretical. Laboratory work shows that BPC-157 increases VEGFR2 expression and promotes blood-vessel growth in cell and animal models [5]. A 2025 review reasons that the same pathways matter to tumors and labels the resulting risk unverified [4]. Whether this applies to people is unknown, because the human data are too limited to answer it [1][7].
What happens to BPC-157 in the body?
In rats and dogs the intact peptide had an elimination half-life under 30 minutes. In rats, radiolabelled peptide was broken into small fragments and single amino acids that enter normal amino acid metabolism, and excretion ran mainly through urine and bile [3]. Intramuscular bioavailability was about 14-19% in rats and 45-51% in dogs [3]. Dose ranges reported in the literature are collected in the BPC-157 dosing reference.
See also: all side-effects references, BPC-157 monograph, product page.
References
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal. 2025;21(4):485-495. https://doi.org/10.1177/15563316251355551
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665. https://doi.org/10.1016/j.yrtph.2020.104665
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. https://doi.org/10.3389/fphar.2022.1026182
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals. 2025;18(2):185. https://doi.org/10.3390/ph18020185
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. https://doi.org/10.1007/s00109-016-1488-y
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159. https://doi.org/10.1007/s00441-019-03016-8
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625. https://doi.org/10.3390/pharmaceutics18050625
- Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. https://doi.org/10.1007/s10787-006-1531-7
- Lee E, Padgett B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain https://pubmed.ncbi.nlm.nih.gov/34324435/.
- Lee E, Walker C, Ayadi B. (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study https://pubmed.ncbi.nlm.nih.gov/39325560/.
- Lee E, Burgess K. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study https://pubmed.ncbi.nlm.nih.gov/40131143/.
- Sikiric P, Petek M, Seiwerth S, et al. (inventors), WO1998052973A1 (1998). New BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy https://patents.google.com/patent/WO1998052973A1/en.
- U.S. Food and Drug Administration (2026). FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (Free Base) and BPC-157 Acetate), PCAC briefing document https://www.fda.gov/media/193343/download.